당뇨병성 말초신경병증 치료 = Management of Diabetic Peripheral Neuropathy

다국어 초록 (Multilingual Abstract)

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus. The prevalence of neuropathic pain is estimated to occur in about 30-50% of all diabetic patients. Clinical symptoms vary depending on the nerves affected, and may include both positive and negative symptoms. Many patients with DPN experience pain or discomfort, anxiety, depression, and limitations in activity, which can significantly impact their physical, emotional, and social well-being. Early diagnosis is essential for the successful management of DPN. Routine management consists of glucose and risk factor control, and symptomatic relief, along with therapies designed to target the underlying disease pathology. Pharmacological treatment of DPN includes tricyclic compounds, serotonin noradrenalin reuptake inhibitors, the antioxidant α-lipoic acid, anticonvulsants, opiates, membrane stabilizers, topical capsaicin, and other drugs. Management of DPN must be tailored to each individual, and depends on a variety of factors, including disease severity and response to treatment. (Korean J Med 2015;89:277-281)

참고문헌 (Reference)

1 Tesfaye S, "Vascular risk factors and diabetic neuropathy" 352 : 341-350, 2005

2 Berger A, "Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy" 23 : 251-258, 2007

3 Ziegler D, "Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis" 21 : 114-121, 2004

4 Ziegler D, "Treatment of diabetic polyneuropathy: Update 2006" 1084 : 250-266, 2006

5 Keen H, "Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group" 16 : 8-15, 1993

6 Hollingshead J, "Tramadol for neuropathic pain" CD003726-, 2006

7 McCleane G, "Topical application of doxepine hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain; a randomized, double-blind, placebo-controlled study" 49 : 574-579, 2000

8 Tesfaye S, "The prevalence of diabetic neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study" 39 : 1377-1384, 1996

9 Dyck PJ, "The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study" 43 : 817-824, 1993

10 Jensen MP, "The impact of neuropathic pain on health-related quality of life: review and implications" 68 : 1178-1182, 2007

11 Boulton AJ, "The global burden of diabetic foot disease" 366 : 1719-1724, 2005

12 Diabetes Control and Complications Trial Research Group, "The effect of intensive diabetes therapy on the development and progression of neuropathy" 122 : 561-568, 1995

13 Valk GD, "The assessment of diabetic polyneuropathy in daily clinical practice:reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination" 20 : 116-118, 1997

14 Dyck PJ, "Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial" 42 : 157-164, 2010

15 Candrilli SD, "Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy" 21 : 306-314, 2007

16 Kim SS, "Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea" 103 : 522-529, 2014

17 Rosenstock J, "Pregabalin for the treatment of painful diabetic peripheral neuropathy:a double-blind, placebo-controlled trial" 110 : 628-638, 2004

18 Sindrup SH, "Pharmacologic treatment of pain in polyneuropathy" 55 : 915-920, 2000

19 Dworkin RH, "Pharmacologic management of neuropathic pain: evidence-based recommendations" 132 : 237-251, 2007

20 Ziegler D, "Oral treatment with a-lipoic acid improves symptomatic diabetic polyneuropathy – The SYDNEY 2 trial" 29 : 2365-2370, 2006

21 Gaede P, "Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes" 348 : 383-393, 2003

22 Inzucchi SE, "Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)" 35 : 1364-1379, 2012

23 Boulton AJ, "Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy" 15 : 508-514, 1998

24 Rose MA, "Gabapentin: pharmacology and its use in pain management" 57 : 451-462, 2002

25 Backonja M, "Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus; a randomized controlled trial" 280 : 1831-1836, 1998

26 Action to Control Cardiovascular Risk in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes" 358 : 2545-2559, 2008

27 Chong MS, "Diabetic painful neuropathy: current and future treatment option" 67 : 569-585, 2007

28 Vinik AI, "Diabetic neuropathies" 43 : 957-973, 2000

29 Gore M, "Burden of illness in painful diabetic peripheral neuropathy:the patients’ perspectives" 7 : 892-900, 2006

30 Boulton AJ, "American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association" 28 : 956-962, 2005

31 Finnerup NB, "Algorithm for neuropathic pain treatment: an evidence based proposal" 118 : 289-305, 2005

32 Dworkin RH, "Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations" 60 : 1524-1534, 2003